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Abstract
The screening method, which employs readily available data, is an inexpensive and quick means of estimating vaccine
effectiveness (VE). We compared estimates of effectiveness of heptavalent pneumococcal conjugate vaccine (PCV7) against
invasive pneumococcal disease (IPD) using the screening and case-control methods. Cases were children aged 19–35
months with pneumococcus isolated from normally sterile sites residing in Active Bacterial Core surveillance areas in the
United States. Case-control VE was estimated for 2001–2004 by comparing the odds of vaccination among cases and
community controls. Screening-method VE for 2001–2009 was estimated by comparing the proportion of cases vaccinated
to National Immunization Survey-derived coverage among the general population. To evaluate the plausibility of screening-
method VE findings, we estimated attack rates among vaccinated and unvaccinated persons. We identified 1,154 children
with IPD. Annual population PCV7 coverage with $1 dose increased from 38% to 97%. Case-control VE for $1 dose was
estimated as 75% against all-serotype IPD (annual range: 35–83%) and 91% for PCV7-type IPD (annual range: 65–100%). By
the screening method, the overall VE was 86% for $1 dose (annual range: 2240–70%) against all-serotype IPD and 94%
(annual range: 62–97%) against PCV7-type IPD. As cases of PCV7-type IPD declined during 2001–2005, estimated attack
rates for all-serotype IPD among vaccinated and unvaccinated individuals became less consistent than what would be
expected with the estimated effectiveness of PCV7. The screening method yields estimates of VE that are highly dependent
on the time period during which it is used and the choice of outcome. The method should be used cautiously to evaluate VE
of PCVs.
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Introduction
The World Health Organization encourages countries that
introduce pneumococcal conjugate vaccine (PCV) into their
routine childhood immunization system to monitor the impact
of the vaccine and the vaccination program on pneumococcal
disease [1]. Many countries, including the United States,
administer a 3-dose infant schedule plus a booster dose in the
second year of life. The United States first introduced heptavalent
PCV (PCV7; Prev[e]nar, Pfizer) in 2000 which was replaced by
13-valent vaccine (PCV13) in 2010. Other countries have
introduced the vaccine using other regimens, in particular, 2
doses for infants plus a booster dose or 3 infant doses without a
booster.
The efficacy of PCV is not generally in dispute; the randomized
controlled trial (RCT) remains the gold standard for calculating
vaccine efficacy. A recent meta-analysis of 11 published RCTs in a
number of settings found that the efficacy of a complete infant
schedule of PCV7 was 80% (95% confidence interval [CI] 58–
90%) against IPD caused by serotypes in PCV7 (PCV7-serotype
IPD) and 58% (95% CI 29–75%) against IPD caused by any
serotype (all-serotype IPD) [2]. The vaccine has demonstrated
efficacy when at least 3 doses are given in the first year of life;
randomized controlled trials with 2 doses in the first year of life
have not been conducted.
Once vaccine has been introduced into a routine immunization
program, RCTs are no longer ethical. High-quality pneumococcal
surveillance can be used to assess population-level impact, but
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estimating vaccine effectiveness–how well the vaccine performs in the
field under real world circumstances–must be done in divergent
settings through observational studies, such as those using a case-
control design. In contrast to RCTs which measure efficacy,
observational studies can provide estimates of vaccine effective-
ness. Case-control studies have limitations inherent in observa-
tional study designs, but despite that they have been quite useful in
estimating vaccine effectiveness post-licensure. A large case-
control study of vaccine effectiveness in the U.S. showed that
one or more doses of PCV7 was highly effective (96% [95% CI
93–98%] against PCV7-serotype IPD among healthy children;
72% [95% CI 65–78%] against all-serotype IPD), and that even a
single dose before eight months of age was effective against PCV7-
type IPD (73% [95% CI 43–87%]) [3].
A potentially less resource-intensive technique of calculating
vaccine effectiveness is the screening method [4,5]. This method is
a variant of the case-control and cohort methods where, instead of
choosing one or more individual controls per case, the entire
population at risk (or a representative, i.e., random, sample of the
population) is used as a reference group [6]. To calculate vaccine
effectiveness using this method, only three data points are needed
from a given population: (1) the number of IPD cases, often
available from pneumococcal surveillance, (2) the number of cases
vaccinated, also often available from pneumococcal surveillance,
and (3) the percent of the population vaccinated, often calculated
from vaccine coverage surveys. No population-based denominator
data are needed. In contrast with prospectively enrolled case-
control studies and RCTs, the screening method leverages data
being collected for other purposes and is, therefore, considerably
less resource-intensive. This method has been proposed as a first
‘‘screening’’ step to determine if further evaluation is warranted
[4], and it has been previously used to measure effectiveness of
vaccines against Haemophilus influenzae type b [7], pertussis [8],
measles [9], meningococcus [10], mumps [11], and influenza [12],
but never, to our knowledge, PCV7. In addition, the screening
method has not been validated against other methods of
calculating vaccine effectiveness, such as the case-control method.
The U.S. conducts multisite, active, population-based surveil-
lance for IPD and annual national surveys of vaccination
coverage, both of which provide the data needed for the screening
method [13,14]. The IPD surveillance was used as a platform for
the case-control study of PCV7 effectiveness soon after PCV7 was
introduced into the U.S. [3], presenting the opportunity to
compare vaccine effectiveness estimates using the screening
method with those of another method. The aim of this current
analysis was to compare vaccine effectiveness estimates from the
screening method with those from the concurrent case-control
study and the scientific literature.
Methods
Population Vaccine Coverage Surveys
Annual population PCV7 vaccine coverage in pneumococcal
surveillance areas was estimated using the U.S. National
Immunization Survey (NIS), a random-digit-dialing telephone
survey of caregivers of children 19–35 months of age that is
followed by mailed surveys to immunization providers as described
in previous publications [15]. The NIS is sponsored by the Centers
for Disease Control and Prevention (CDC) and has been
conducted since 1994 to monitor vaccination coverage at the
national, state, and in select local in the United States.
Invasive Pneumococcal Disease Surveillance
To match the age group surveyed in the NIS, children who
were age 19–35 months in the years from 2001 to 2009, the nine
years following PCV7 introduction in the U.S. in 2000, were
eligible for inclusion (e.g., eligible children 19–35 months of age in
2001 were born from February 1998 to June 2000). Cases of IPD
had Streptococcus pneumoniae isolated from normally sterile sites and
resided in one of 10 population- and laboratory-based pneumo-
coccal Active Bacterial Core surveillance areas in the U.S., a
surveillance system supported by CDC’s Emerging Infections
Program Network [13]. Pneumococcal isolates were sent to
reference laboratories at the Minnesota Department of Health
or CDC for serotyping by the Quellung reaction and PCR [16].
Case-patients lived in California (San Francisco County, Alameda,
and Contra Costa counties), Colorado (5-county Denver area),
Connecticut (entire state), Georgia (20-county Atlanta metropol-
itan area), Maryland (Baltimore City and 5 neighboring counties
[Baltimore metropolitan area]), Minnesota (Minneapolis and St.
Paul in 2001–2002 and entire state beginning in 2002), New
Mexico (beginning in 2004), New York (15-county Rochester and
Albany areas), Oregon (3-county Portland metropolitan area), and
Tennessee (Davidson, Hamilton, Knox, Shelby, and Williamson
Counties). According to 2009 census estimates, the surveillance
areas included 640,000 children 19–35 months of age [17].
Surveillance officers routinely contacted all clinical laboratories
in their areas to identify cases of IPD and conducted periodic
audits of laboratory records to ensure complete case ascertain-
ment. Demographics, clinical course, and vaccination status of
case-patients were determined through chart review using
standardized forms. Recurrent cases were excluded; the first case
was included. Study personnel obtained vaccination history from
the primary healthcare provider or the provider where the patient
reported receiving vaccinations; vaccination registries were also
used in Tennessee, Georgia, Minnesota, New Mexico, and
Oregon. Cases without recorded vaccination histories were
excluded.
Vaccine Effectiveness
Vaccine effectiveness is defined as the percentage reduction in
the incidence of disease among vaccinated persons compared with
unvaccinated persons, as given in the following equation:
Vaccine Effectiveness
~
Incidence in unvaccinated population{Incidence in vaccinated population
Incidence in unvaccinated population
|100%
~ 1{
Incidence in vaccinated population
Incidence in unvaccinated population
 
|100%
~1{
Number of cases that are vaccinated
Number of total population that is vaccinated
 
Number of cases that are unvaccinated
Number of total population that is unvaccinated
 |100%
Attack rates can be substituted for incidence, but in either case,
some form of population denominators are needed to calculate
vaccine effectiveness. The case-control method does not require
population denominators but does need controls as a comparison
group. Neither is needed for the screening method, which
approximates vaccine effectiveness by comparing the vaccinated
proportion of children with disease with the vaccinated proportion
of children in the general population [4,5]. If we assume that the
vaccinated and unvaccinated cases arise from the same popula-
tion, then we can manipulate the vaccine effectiveness equation
algebraically to remove the need for population denominators (i.e.,
Pneumococcal Vaccine Effectiveness Using Screening
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the number of the total population that is vaccinated or
unvaccinated) as given below, where n is the number of total
cases and N is the number in the total population:
Vaccine Effectiveness
~1{
Number of cases that are vaccinated
Number of total population that is vaccinated
 
Number of cases that are unvaccinated
Number of total population that is unvaccinated
 |100%
~1{
Proportion cases vaccinated|n
Proportion total population vaccinated|N
 
1{Proportion cases vaccinatedð Þ|n
1{Proportion total population vaccinatedð Þ|N
 |100%
~1{
Proportion cases vaccinated
Proportion total population vaccinated
 
1{Proportion cases vaccinated
1{Proportion total population vaccinated
 |100%
~
Proportion cases vaccinated
1{Proportion cases vaccinated
 
|
1{Proportion total population vaccinated
Proportion total population vaccinated
 
|100%
An attack rate is the number of cases in a particular population
divided by the total count of that population. Since the screening
method is used in situations where population denominators are
not available or reliable, incidence and attack rates often cannot be
calculated. However, they can be estimated using the same
minimal inputs as those used for the screening method. Therefore,
estimating attack rates from vaccine effectiveness estimates can be
a useful way to check the validity of the vaccine effectiveness
estimates; namely, attack rates should be higher among the
unvaccinated population than the vaccinated if a vaccine is
effective. We estimated attack rates in the following manner: The
number of cases who had been vaccinated was divided by the
estimated total number of people vaccinated in the population; an
analogous rate was computed for non-vaccinated cases. The total
vaccinated population was computed as the product of estimated
coverage rates and estimated total population in the relevant
geographic area; in this case, we assumed a hypothetical
population of 1 million children aged 19–35 months. This
hypothetical population was chosen because it is an even number
and a reasonable estimate of the true population. Non-vaccinated
population was the complement. These attack rates were scaled to
cases per 100,000 population for convenience of dealing with
integers.
Using the screening methods, we calculated the vaccine
effectiveness of PCV7 against all-serotype IPD and PCV7-serotype
IPD (i.e., 4, 6B, 9V, 14, 18C, 19F, and 23F) for children who
received at least one PCV7 dose and separately for children who
received at least 4 doses. Children that met the defined schedule
were compared with children who had received no vaccination;
partially vaccinated cases were excluded from the 4-dose analysis
[4,7]. We calculated annual vaccine effectiveness estimates using
data from each given year and overall vaccine effectiveness
estimates by pooling that data from all years together and
calculated vaccine effectiveness from the pooled data.
For the matched case-control method, vaccine effectiveness was
calculated using conditional logistic regression by comparing the
odds of cases being vaccinated to the odds of community controls
being vaccinated. We did not adjust for confounding to make this
analysis comparable to the screening method analysis used here.
Using previously collected data and methods from the Whitney, et
al., (2006) case-control study [3], we were able to calculate using a
new analysis the vaccine effectiveness of the $1-dose schedule for
all-serotype and PCV7-serotype IPD through 2004, the years of
the case-control study. Due to low numbers of cases, we were
unable to calculate the vaccine effectiveness of the 4-dose schedule
using the case-control method; therefore, we compared the
estimates from the screening method with those from the case-
control methods for the $1-dose schedule.
Human Subjects Review
Pneumococcal case reporting and isolate collection were
considered to be public health surveillance activities exempt from
CDC institutional review. All local institutional review boards at
the participating surveillance sites reviewed the protocol, and
approval was obtained when deemed necessary by participating
sites. These sites included Emory University School of Medicine,
Atlanta, Georgia; Vanderbilt University School of Medicine,
Nashville, Tennessee; Minnesota Department of Health, St. Paul,
Minnesota; Colorado Department of Health and the Environ-
ment, Denver, Colorado; Rochester University School of Medi-
cine, Rochester, New York; University of California, Berkeley,
Berkeley, California; Oregon Department of Health, Portland,
Oregon; New Mexico Department of Health, Santa Fe, New
Mexico; Johns Hopkins Bloomberg School of Public Health,
Baltimore, Maryland; and Connecticut Department of Public
Health, Hartford, Connecticut. Data from the National Immuni-
zation Survey is publicly available and not subject to human
subjects review. Analyses using data from the PCV7 case-control
study are secondary data analyses, meaning that we analyzed
existing data that had been collected for another reason; human
subjects review for the case-control study is discussed in the
original article [3].
Results
Trends in Invasive Pneumococcal Disease
During the 9-year study period, 1154 children with IPD aged
19–35 months were identified; 639 (55.4%) were female, 222
(22.7%) had underlying conditions, 549 (47.7%) were hospitalized,
and 17 died (1.5%). Two-thirds of the children with IPD had a
known vaccine history (n=779, 67.5%). Most of the IPD isolates
had a known serotype (n=996, 86.3%), and of those, three-
quarters of the cases had a known vaccine history (n=743, 74.6%).
There was a steep decline in the number of all-serotype IPD cases
with a known vaccine history from 103 cases in 2001 to a low of 53
cases in 2003 (Table 1). The number of IPD cases caused by
serotypes included in PCV7 with a known vaccine history
decreased 99% from 73 in 2001 to 1 in 2009; most of the decline
was in the first few years following PCV7 introduction.
Trends in Population Vaccine Coverage
The vaccine coverage among cases and in the general
population increased quickly from 2001 to 2009 (Table 1). Among
the general population, annual PCV7 coverage increased for the
$1-dose schedule from 38% to 97% and for the 4-dose schedule
from 2% to 81%. PCV7 coverage for both the $1- and 4-dose
schedules was slightly lower in most years for cases of PCV7-
serotype IPD compared with all-serotype IPD cases.
Vaccine Effectiveness
Using the screening method, annual PCV7 effectiveness against
all-serotype IPD was variable across years, ranging from 2240%
to 70% (86% overall) for the $1-dose schedule and from 2221%
to 42% (68% overall) for the 4-dose schedule (Table 1). Vaccine
effectiveness against PCV7-serotype IPD was less variable (for $1
dose schedule, annual range from 2001 to 2009: 62–97%, 94%
overall; for 4-dose schedule, annual range: 74–100.0%, 97%
Pneumococcal Vaccine Effectiveness Using Screening
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Table 1. Vaccine effectiveness of at least one dose and 4 or more doses of 7-valent pneumococcal conjugate vaccine (PCV7)
against all-serotype invasive pneumococcal disease (IPD) and PCV7-serotype IPD among children 19–35 months of age with
vaccine histories using unadjusted screening and case-control methods.
Year
2001 2002 2003 2004 2005 2006 2007 2008 2009 Overall
All-serotype IPD*
Total number of cases 103 64 53 76 71 98 96 82 100 743
$1 doses PCV7
Vaccine coverage, %
Cases 16 66 91 96 96 98 96 98 99 83
Population 38 74 90 92 95 96 98 98 97 89
Estimated attack rate, %
Vaccinated 5 5 5 8 7 10 9 8 10 8
Unvaccinated 14 8 5 4 6 5 16 8 3 11
Vaccine effectiveness, %
Screening method 70 33 24 2104 217 298 41 2 2240 86
Case-control method 83
(66, 92)
70
(40,85)
71
(27, 92)
35
(2261, 88)
{ { { { { 75
(62, 84)
4 doses PCV7
Vaccine coverage, %
Cases 2 45 76 91 91 97 95 97 99 52
Population{ 2 21 39 45 53 70 77 83 81 52
Estimated attack rate, %
Vaccinated 6 4 2 4 3 7 7 7 8 6
Unvaccinated 9 4 3 2 4 4 13 7 3 6
Vaccine effectiveness, %
Screening method 39 22 19 283 5 298 42 7 2221 68
Case-control method " " " " " " " " " "
PCV7-serotype IPD*
Total number of cases 73 27 8 11 5 5 2 3 1 135
$1 dose PCV7
Vaccine coverage, %
Cases 6 37 63 82 80 100 50 100 100 31
Population 38 74 90 92 95 96 98 98 97 89
Estimated attack rate, %
Vaccinated 1 1 1 1 0 1 0 0 0 1
Unvaccinated 11 7 3 3 2 0 4 0 0 8
Vaccine effectiveness, %
Screening method 91 79 82 62 79 9 97 9 9 94
Case-control method 95
(89, 99)
84
(56, 94)
100
(19, 100) u
65
(2489, 98)
{ { { { { 91 (80, 96)
4 doses PCV7
Vaccine coverage, %
Cases 0 6 25 60 0 100 50 100 100 8
Population{ 2 21 39 45 53 70 77 83 81 52
Estimated attack rate, %
Vaccinated 0 0 0 0 0 0 0 0 0 0
Unvaccinated 7 3 2 1 1 0 3 0 0 4
Pneumococcal Vaccine Effectiveness Using Screening
PLoS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e41785
overall). The screening method produced vaccine effectiveness
estimates for the $1-dose schedule that were consistently lower
but similar to those using the case-control method for PCV7-
serotype IPD: In three of the four years during which estimates
were available for both methods, the point estimate derived from
the screening method differed from the point estimate derived
from the case-control method by #5%. For all-serotype IPD, on
the other hand, estimates of vaccine effectiveness differed by
.10% for all four years where we had both estimates and by
.30% for three of four years (Table 1).
Estimated Attack Rates
In general for PCV7-serotype IPD, the estimated attack rates,
corresponding to the screening-method inputs, among the
unvaccinated were higher than among the vaccinated (Table 1).
The attack rates were more variable for all-serotype IPD,
particularly after the first year or two after vaccine introduction.
As cases of PCV7-type IPD declined during 2001–2005, attack
rates for all-serotype IPD among vaccinated and unvaccinated
individuals became more similar, while attack rates for PCV7-type
IPD remained consistent with effectiveness of PCV7.
Discussion
Is there a role for using the screening method to calculate
vaccine effectiveness of PCV7? Yes, but it is a limited role. The
term ‘‘screening method’’ was coined because this method was
designed to be used as a quick, preliminary analysis when
incidence and attack rate data are not available. In clinical
medicine, screening tests are not expected to be diagnostic but
rather to identify patients who need further evaluation for
diagnosis and treatment. Similarly, vaccine effectiveness estimates
derived from the screening method may require subsequent
confirmation with more accurate and valid methods. Similar to
diagnostic screening, a plausible result does not necessarily equate
to a valid estimate of vaccine effectiveness. The computed and
corresponding attack rates are an additional de facto screen on use
of the same data inputs.
Based on results of randomized clinical trials and case-control
studies, for the full-vaccine regimen and the vaccine-specific
outcome PCV effectiveness estimates generally above 90% are
credible. At the reduced dosage but still for the specific outcome,
vaccine effectiveness estimates in the range of 80% are also
credible. After the first 2–3 years and when using a non-specific
endpoint such as IPD caused by all serotypes, the vaccine
effectiveness estimates are highly variable and not what would be
expected theoretically. We would expect vaccine effectiveness
estimates to be higher against PCV7-type disease compared with
all-serotype IPD. We would also expect that the complete 4-dose
schedule would be more effective than receiving only 1 or more
doses. Further, we would expect that the vaccine effectiveness
estimates against all-serotype IPD would decline over time as
fewer IPD cases are caused by serotypes included in the vaccine.
These expectations were fulfilled, suggesting that the screening
method may yield valid estimates of vaccine effectiveness,
particularly for PCV7-type IPD during the first few years post-
introduction, when our estimates were similar to those from
published randomized controlled trials and comparable case-
control studies [2,3].
The estimated attack rates provide a critical opportunity to
evaluate the believability of the estimates. If the screening results
are to be credible, then the corresponding ARs must also be
plausible. Even in the case of ‘‘good’’ effectiveness estimates, if the
attack rates are impossible or unlikely, then the VE rates are
suspect. For vaccines known by other means to be effective, such
as PCV7, we would expect the attack rate to be lower in the
vaccinated than the unvaccinated. The near-zero attack rate for
PCV7-serotype IPD for the 4-dose schedule is what one would
expect, as is the gradually declining attack rate in the unvaccinat-
ed, presumably due to herd effect. Similarly, the attack rates for
PCV7-type IPD for the $1-dose schedule are low and gradually
declining over the study period. The implausible attack rates for
all-serotype IPD more than two years after vaccine introduction
suggest that the screening method cannot be used reliably to
estimate effectiveness of PCV7 against all-serotype IPD once the
proportion of all IPD caused by PCV7 serotypes falls precipitously
and non-PCV7 type disease increases.
Although the screening method simply applies the basic
equation for calculating vaccine effectiveness, it is subject to
biased estimates as is any secondary data analysis or observational
study. However, because the screening method requires data that
may be collected for other purposes, future PCV-adopting
countries may consider applying this method as PCV immuniza-
tion programs are rolled out worldwide. Accordingly, since we’ve
shown vaccine effectiveness estimates using this method to be
erratic, we submit that it is critical to understand and review the
underlying assumptions and features of the method [4,5].
Estimates of effectiveness from the screening method are very
sensitive to minor errors in input estimates. For example, vaccine
effectiveness will be overestimated if the population vaccine
coverage is overestimated (Figure 1, adapted from [4]). For
pneumococcal vaccine and other vaccines incorporated into the
routine infant immunization system in the U.S. and many other
countries, vaccine coverage rises quickly, which will likely
Table 1. Cont.
Year
2001 2002 2003 2004 2005 2006 2007 2008 2009 Overall
Vaccine effectiveness, %
Screening method 100 93 92 74 100 9 97 9 9 97
Case-control method " " " " " " " " " "
*Includes only cases with vaccine history available.
{Unable to calculate because the original case-control study did not collect data on controls after 2004 [3].
{Partially vaccinated individuals (i.e., 1, 2, or 3 PCV7 doses) were excluded from this calculation.
"Unable to calculate vaccine effectiveness estimates for 4-dose schedule using the case-control method due to low numbers of cases.
uConfidence intervals calculated using Fisher’s exact test.
9Unable to calculate because of 100% vaccine coverage among case.
doi:10.1371/journal.pone.0041785.t001
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adversely affect vaccine effectiveness estimates produced by the
screening method 2–4 years after vaccine introduction. In
addition, PCV7-serotype IPD declined dramatically after PCV7
introduction. Extrapolating from small numbers when case counts
decline after vaccine introduction can lead to wide variability in
vaccine effectiveness estimates. An additional contributing factor is
that widespread PCV7 use leads to herd immunity, which could
account for lower attack rates in the unvaccinated than otherwise
expected and translate to lower estimates of vaccine effectiveness.
A potential weakness of the screening method is that it may not be
as reliable for evaluating vaccines that create high levels of herd
immunity, such as pneumococcal in contrast to measles vaccines.
We also assumed that the vaccinated and unvaccinated cases arise
from the same population, which may not be the case in many
developing countries.
The screening method assumes that population vaccine
coverage is relatively stable and a sufficiently large proportion of
the population is unvaccinated to allow the disease to remain
endemic. This applies to the epidemiology of measles vaccination,
a disease for which the screening method has been successfully
used and for which the method was originally described [4].
However, based on our experience in the U.S., this was not the
case with PCV7 coverage (which rose quickly) and IPD (which
dropped soon after introduction). In addition, increases in non-
vaccine serotype IPD in the years following vaccine introduction
may lead to inaccurate estimates of vaccine effectiveness because
such increases violate the ‘‘steady state’’ assumption inherent in
single-point vaccine coverage or disease incidence inputs [18].
This analysis is subject to the following limitations. First,
because the NIS limits its survey to children 19–35 months of
age, we limited this analysis to children with IPD who were 19–
35 months of age, which is slightly older than the peak age of
IPD in young children [19]; vaccine effectiveness estimates may
differ by age, and we were unable to calculate vaccine
effectiveness for the commonly studied age group of children
,5 years of age. Second, we were limited by the post-hoc case-
control analysis in this manuscript, and we were unable to
calculate effectiveness estimates using case-control methodology
for the years 2005–2006 and for 4-dose PCV7 schedules. This
also affected the number of cases with a complete vaccine
history, which was only gathered reliably for patients enrolled in
the case-control study and in the later years of the IPD
surveillance. We limited our analysis to patients with available
vaccine histories, which could bias trends shown in IPD. Third,
vaccine coverage estimates should represent the populations
from which the cases come. In our situation, the vaccine
coverage estimates included the population at risk from the
pneumococcal surveillance areas, but the sampling methodology
of ABCs surveillance and the NIS precluded exactly matching
populations. Fourth, we did not calculate confidence intervals
for the screening method vaccine effectiveness estimates because
the method uses a simple algebraic and deterministic equation.
Fifth, the estimated attack rates assume a stable population,
which may not be the case. Lastly, we were not able to adjust for
known confounders such as underlying medical conditions of
case-patients with IPD with the screening method [3]. The
authors note that the overall vaccine effectiveness estimates may
seem counterintuitively high compared with the annual
estimates; this is a result of pooling the data overall to calculate
the vaccine effectiveness and not calculating a mean of the
annual estimates.
With higher valency (10- and 13-valent) pneumococcal
conjugate vaccines now being introduced in many countries
worldwide, there will be an increased need for evaluations of the
impact and effectiveness of pneumococcal conjugate vaccine. The
screening method should be used cautiously to evaluate VE of
PCVs. Those using the screening method should remember that
small differences in the data due to poor quality surveillance can
lead to large differences in vaccine effectiveness estimates. Other
less resource-intensive methods, such as the indirect cohort
method, have been used successfully; however, it requires
serotyping of pneumococcal isolates, cannot estimate vaccine
effectiveness against all-serotype IPD, and may not be able to
account for herd immunity [20]. In summary, the screening
method should only be used as a preliminary test in situations
where the data inputs are valid, more reliable evaluations of
vaccine impact are not feasible, where sufficient cases are
available, and vaccine coverage has not peaked in the general
population.
Figure 1. Estimated vaccine effectiveness using the screening method. This figure was created using hypothetical data created by the
authors, and is adapted from a similar figure in Orenstein, et al. (1985) [4]).
doi:10.1371/journal.pone.0041785.g001
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